Showing results (191-200 of 220) with videos related to
Sort By:
Pageof 22
The New England Journal of Medicine|October 19, 2012
Ustekinumab induction and maintenance therapy in refractory Crohn's diseaseWilliam J Sandborn, Christopher Gasink, Long-Long Gao, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2010
African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunityJames P Lodolce, Lauren E Kolodziej, Lesley Rhee, et al.Inflammatory Bowel Diseases|August 22, 2020
Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United StatesBenjamin L Cohen, Zane R Gallinger, Christina Ha, et al.Alimentary Pharmacology & Therapeutics|October 15, 2024
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC ConsortiumParambir S Dulai, Lauren Balmert Bonner, Charlotte Sadler, et al.Nature Communications|April 28, 2026
Spatial transcriptomics atlas of inflammatory bowel disease to guide implementation in research consortiums and clinical trialsYiming Li, Cenfu Wei, Wenjing Yang, et al.Lancet (London, England)|June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E Sands, Peter M Irving, Timothy Hoops, et al.The Journal of Clinical Investigation|February 8, 2024
Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancerTriet M Bui, Lenore K Yalom, Edward Ning, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 16, 2024
Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In UteroRalley Prentice, Emma Flanagan, Emily K Wright, et al.Inflammatory Bowel Diseases|August 29, 2009
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart, Stephan R Targan, Axel U Dignass, et al.Journal for Immunotherapy of Cancer|November 14, 2024
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse eventsMalek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, et al.Pageof 22